Skip to main content

Table 1 Details on the included studies in the meta-analysis

From: Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis

Author Year of publication Follow-up time (months) Sample size Patient mean age (years) Sex Bisphosphonates/control group Intervention protocol
Hennigs T 2002 12 66 51.5 29/27 42/24 Subgroup 1: oral alendronate 10 mg/day for 10 weeks
        Subgroup 2: oral alendronate 20 mg/day for 5 weeks
Arabmotlagh M 2006 72 51 62.5 26/25 27/24 Subgroup 1: oral alendronate 20 mg/day for 2 months, thereafter 20 mg/day for 4 months
        Subgroup 2: oral alendronate 20 mg/day for 2 months, thereafter 20 mg/day for 6 months
Arabmotlagh M 2009 72 49 62.5 25/24 29/20 Subgroup 1: oral alendronate 10 mg/day for 10 weeks
        Subgroup 2: oral alendronate 20 mg/day for 5 weeks
Iwamoto N 2011 12 60 65 14/46 20/40 Oral alendronate 5 mg/day for 48 weeks
Skoldenberg OG 2011 24 73 60 30/43 36/37 Oral risedronate 35 mg/week for 6 months
Tapaninen TS 2010 60 16 61.4 7/9 7/9 Oral alendronate 10 mg/day for 6 months
Trevisan C 2010 12 91 64.7 53/58 42/49 Oral clodronate 100 mg/day for 10 days, thereafter 100 mg/week for 50 weeks
Venesmaa PK 2001 6 13 62.62 6/7 8/5 Oral alendronate 10 mg/day for 6 months
Yamaguchi K 2005 12 43 68.5 0/44 26/17 Subgroup 1: oral etidronate 200 mg/day for 2 weeks, followed by 12 weeks of calcium lactate of 500 mg/day, the cycle was repeated four times
        Subgroup 2: oral etidronate 400 mg/day for 2 weeks, followed by 12 weeks of calcium lactate of 500 mg/day, the cycle was repeated four times
Yamasaki S 2007 6 40 66.7 4/36 19/21 Oral risedronate 2.5 mg/week for 6 months